Keywords: Factor VIII, F8, hemophilia A, inhibitors, HLA, nonsynonymous SNPs, haplotypes, intron 22 inversion The online version of the article contains a data supplement. that differed from those of putative proteins encoded by their F8 genes did not show high-avidity tetramer binding, whereas positive-control staining of tetanus-specific CD4 T cells was routinely successful. African Americans with an intron-22 inversion mutation showed a ~3X higher inhibitor incidence than Caucasians with the same mutation (OR=2.75(1.3-5.8, P=0.008), but this did not correlate with any of the ns-SNPs. We conclude that immune responses to 'sequence-mismatched' FVIII products are unlikely to contribute appreciably to the inhibitor incidence in African Americans.
Introduction
Hemophilia A (HA) is an X-linked disorder caused by mutations in the F8 gene resulting in lack of circulating or defective factor VIII (FVIII). Approximately 25% of severe HA patients develop neutralizing antibodies ("inhibitors") following FVIII infusions, which can cause severe bleeding that is difficult and expensive to manage [1] . The development of inhibitory antibodies requires Tcell help. For T-cell stimulation to occur, one or more peptides must contain epitopes that bind effectively to MHC Class II (e.g. HLA-DRB1) on antigen presenting cells. If this Class II-peptide For personal use only. on April 12, 2017 . by guest www.bloodjournal.org From complex is then recognized by a T-cell receptor, Class II-peptide-T-cell receptor interactions lead to proliferation and cytokine secretion promoting anti-FVIII antibody production, class switching and affinity maturation. Infusions of therapeutic FVIII expose patients' immune systems to amino acid sequences absent from their endogenous hemophilic FVIII (if any), and recognition of these sequences by T-effector cells can lead to inhibitor development.
Mild and moderately severe HA is generally caused by minor FVIII sequence variations [2] . The incidence of inhibitors in this population is low because they typically are not exposed to as much therapeutic FVIII as severely affected patients and the region(s) of infused FVIII that differ from their endogenous FVIII sequences are usually not recognized as epitopes. However, some of these patients do develop clinically significant inhibitors, especially if they receive intensive FVIII treatment in a setting of trauma or inflammation [3] [4] [5] . Several studies have demonstrated that mild HA inhibitor subjects showed HLA-restricted T-cell responses to epitopes that included the wild-type FVIII sequence at the hemophilic missense site [6] [7] [8] . Thus, even slight sequence variations in therapeutic FVIII could contribute to inhibitor risk.
African American HA patients have been reported to experience an increased inhibitor incidence [9] [10] [11] . Three ns-SNPs in the F8 gene encode non-hemophilia-causing amino acid sequence variations (FVIII-H484, FVIII-E1241 and FVIII-V2238) found in a significant fraction of individuals with Black African ancestry [12] [13] [14] . Earlier studies [13, 14] identified F8 haplotypes H1 (encoding FVIII-R484, D1241, M2238) and H2 (encoding FVIII-R484, E1241, M2238) ( Figure 1 ) in 93% and 7% of 86 Caucasian and 35% and 37% of 67 African American HA subjects studied, respectively, while F8 genes encoding FVIII-H484 (haplotype H4) and FVIII-V2238 (haplotypes H3+H5) were found in 4% and 23% of the African American subjects, respectively, but not in Caucasians. Additional ns-SNPs are being identified by large-scale DNA sequencing efforts, leading to a growing appreciation of the possibility that some patients' MHC For personal use only. on April 12, 2017 . by guest www.bloodjournal.org From Class II may present 'sequence-mismatched' regions of infused FVIII and stimulate T-effector cells, leading to inhibitor development [15] [16] [17] [18] . Recombinant FVIII proteins with R484, either D1241 or E1241, and M2238 are currently used therapeutically. Many HA patients are thus exposed to FVIII products having amino acid sequences mismatched with the putative protein encoded by their hemophilic F8 gene.
A 2009 study of 76 African American HA subjects [14] reported a higher prevalence of inhibitors associated with F8 haplotypes H3+H4 compared to H1+H2. The present study utilized three approaches to investigate relationships between F8 haplotypes, race and inhibitor risk. First, the correlations between F8 haplotypes and inhibitor history were evaluated for 174 African American and 198 Caucasian HA subjects. Second, binding of FVIII peptides with sequences encoded by four ns-SNPs to 11 common MHC(HLA-DRB1) proteins was measured, as MHC binding is a prerequisite for T-cell stimulation. Third, CD4 T cells from 23 subjects who had been treated with 'sequence-mismatched' FVIII products and five controls were analyzed using peptide-loaded MHC(HLA-DRB1) tetramers in an attempt to identify T-cell responses to sequences encoded by ns-SNPs in the F8 gene.
Methods

Subjects' clinical status and polymorphism analysis
417 African American and Caucasian HA subjects, 41 non-HA, 2 HA inhibitor subjects of other races and 3 autoimmune subjects were enrolled in the Personalized Approaches to Therapies for Hemophilia (PATH) study (NIH-NHLBI-1RC2-HL101851), 365 with severe HA and seven with an intron-22 inversion mutation and clotting activity ≥ 1% normal. These 372 subjects are referred to as the study cohort. All provided written informed consent in accordance with the principles of Helsinki. Questionnaires filled out at their clinics summarized their clinical histories.
Blood samples were obtained and genomic DNA isolated using standard protocols. PBMCs
For personal use only. on April 12, 2017 . by guest www.bloodjournal.org From were isolated from heparin-anticoagulated blood by Ficoll-Paque density gradient centrifugation and cryopreserved.
DNA sequences at ns-SNPs encoding FVIII-R484H, FVIII-D1241E and FVIII-M2238V were determined by PCR, a DNA digestion assay, High Resolution Melting reactions and Sanger sequencing. To the extent possible, the FVIII-484, FVIII-1241 and FVIII-2238 sequence loci were cross-checked by comparing RT-PCR, melting curves, DNA digests and sequencing data.
In several cases the sequence chromatograms were checked visually to make the final sequence call. HLA-DRB1 typing was performed by the UCLA Immunogenetics Laboratory (Los Angeles, CA) and additional F8 sequence data were provided by the Texas Biomedical
Research Institute (San Antonio, TX). Pairwise correlations between inhibitor status and race, haplotypes, individual ns-SNPs, HLA-DRB1 and age were evaluated using Fisher's exact 2-way test, followed by logistic regression analysis adjusting for age, F8 haplotype, family relationships and potential exposure to 'sequence-mismatched' FVIII.
Peptide-MHC binding assays and predictions:
Sixteen 20-mer FVIII peptides (Table 1) , plus non-FVIII reference peptides with high-affinity binding to specific recombinant HLA-DRB1 molecules and/or known to elicit HLA-DRB1-restricted T-cell responses (supplemental Table 1), were used for competition binding assays to determine IC 50 values. The peptides corresponded to both versions of sequences encoded by the four ns-SNPs identified previously [13] , and they were designed to potentially allow binding to recombinant MHC(HLA-DRB1) proteins in multiple registers within the peptide-binding groove [19] . The ability of 11 HLA-DRB1 recombinant proteins, whose corresponding alleles are found in ~74% and ~40% of European and African American populations, respectively [20] , to present peptides containing these sequence variants was characterized by quantitative peptide-MHC binding assays measuring displacement of biotinylated reference peptides specific for each HLA-DRB1 [8] . Binding affinity predictions were African American and one Caucasian HA subject (15 severe and one mild HA, seven with a historic peak inhibitor >1 BU/mL) whose F8 gene encoded V2238 and therefore had been treated with a therapeutic FVIII product mismatched at this site with respect to the endogenous sequence encoded by their hemophilic F8 gene; (2) three African American, one Caucasian and one SE Asian severe HA subject (three with and two without a historic peak inhibitor >1 BU/mL) whose F8 gene encoded M2238 as controls (the SE Asian subject was enrolled as an inhibitorpositive control); (3) one African American severe and one mild HA subject with a historic peak inhibitor titer of 11 BU/mL whose F8 gene encoded H484; (4) five severe HA subjects whose endogenous F8 gene encoded D1241, who had at least one HLA-DRB1 shown to bind FVIII-E1241 peptides with moderate to strong affinity, and whose clinical records indicated they had been treated with FVIII-1241E.
Peptides containing FVIII-M2238 and FVIII-V2238, or FVIII-R484 and FVIII-H484, or FVIII-D1241 and FVIII-E1241, were used to stimulate CD4 T cells and were loaded onto tetramers, first in pools of 4 peptides and then as single peptides. Positive control experiments carried out using aliquots of PBMCs utilized peptides corresponding to tetanus epitopes [25] . Tetramerpositive cells (loaded with FVIII or tetanus peptides) were single-cell sorted and also sorted at 250 cells/well using a FACS Aria II (BD Biosciences, San Jose, CA) into 96-well round-bottom For personal use only. on April 12, 2017 . by guest www.bloodjournal.org From plates containing 75 μl 20% human serum T-cell medium, in an attempt to generate T-cell clones and polyclonal lines, respectively. These cells were expanded by stimulating with 2 μ g/ml phytohaemagglutinin (PHA) and 100,000 irradiated PBMCs from subjects with mismatched HLA-DRB1 alleles in 100 μl of 15% human serum T-cell medium. After 24 hrs, 25 μl of natural human IL-2 (Hemagen) diluted 2.5-fold in 15% human serum T-cell media was added to each well. As cultures expanded, filling the bottom of round-bottom wells (~2 weeks), they were transferred to flat-bottom wells and an equal volume of fresh 15% human serum T-cell medium containing a 1:10 dilution of natural human IL-2 was added every 48 hrs. After three weeks, the cells were re-stimulated with PHA and irradiated HLA-mismatched PBMCs. Cells were given an equal volume of fresh 15% human serum T cell medium containing a 1:10 dilution of natural human IL-2 24-48 hrs after re-stimulation and every 2-3 days thereafter for 14 days. The expanded cells were then stained with the same peptide-loaded tetramers used for sorting to determine if they corresponded to T-cell clones or polyclonal lines that specifically bound the tetramer.
Results
Subjects' clinical status and polymorphism analysis
Clinical status and correlations between F8 polymorphisms/haplotypes, HA-causing mutations and inhibitor histories are summarized in Tables 2-5 and supplemental Tables 2-3 . HA-causing mutations were determined for 274/372 and F8 haplotypes for 362/372 subjects.
Polymorphisms encoding variants FVIII-D1241E and FVIII-M2238V showed no significant correlation with inhibitor development, nor did combinations of ns-SNPs comprising F8 haplotypes 1-5. Similar results were obtained when 323 severe unrelated HA probands were analyzed (supplemental Table 2 ), and when only high-responder inhibitors (peak titer >5 BU/mL) were classified as "inhibitor-positive" (supplemental Table 3 ). The most noteworthy difference amongst the various subgroups was that African American subjects with an intron-22
For personal use only. on April 12, 2017 . by guest www.bloodjournal.org From inversion mutation were ~3X as likely to experience an inhibitor as Caucasian subjects with the same mutation (adjusted OR=2.75(1.3-5.8, 95% CI), p=0.008, Table 5 ). This remained significant when only high-responder inhibitors (peak titer >5 BU/mL) were classified as "inhibitor-positive" (supplemental Table 3 ). Subgroups with non-intron-22-inversion mutations were too small to calculate meaningful correlations between other risk factors and inhibitor incidence. Clinical records indicated that up to 91%, 71% and 100% of subjects with haplotypes H1, H2 and (H3-H5), respectively, had been infused or transfused with 'sequence-mismatched' FVIII. This subgroup, which included all subjects who had ever been treated with plasmaderived FVIII or other blood-derived products, including blood transfusions or Factor Eight Inhibitor Bypass Agent, had a significantly higher inhibitor risk (Table 5) .
Peptide-MHC binding assays and predictions:
The affinities of 16 20- Table 6 and summarized briefly below. Representative competition binding curves are shown in Figure 2 .
R484H: R484 peptides had strong affinity for DR0301, DR0403 and DR1501; H484 peptides had moderate affinity for DR0301, DR0403 and DR1501; both R484 and H484 peptides had moderate affinity for DR1104 and DR0404. R776G: R776 peptides had weak-to-moderate affinity for DR0901.
D1241E: D1241 and E1241 peptides had moderate affinity for DR0403. E1241 peptides had moderate-to-strong affinity for DR0901 and moderate affinity for DR1001 and DR0101. D1241 peptides had weak-to-moderate affinity for DR0901.
M2238V: Both M2238 and V2238 peptides had strong affinity for DR0301, strong-to-moderate affinity for DR0403 and moderate affinity for DR0101, DR1104, DR1101 and DR0404.
For personal use only. on April 12, 2017 . by guest www.bloodjournal.org From To summarize, effective peptide-MHC binding is required for T-cell engagement by antigenpresenting cells. Therefore, peptides with weak or no binding affinity to particular MHC proteins would be highly unlikely to provoke CD4 T-cell responses restricted to the corresponding MHC alleles. Several FVIII peptides differing by just one ns-SNP-encoded amino acid bound to particular HLA-DRB1 proteins with different affinities. The most striking difference between these pairs was for peptide E1241-2, which bound DR0901 with higher affinity than peptide D1241-2, suggesting that, if a similar peptide was naturally processed and presented on antigen-presenting cells of a patient who expressed a hemophilic FVIII protein with FVIII-D1241, this might break pre-existing tolerance to FVIII-D1241.
The computer algorithms ProPred and NetMHCIIpan2 correctly identified many of the FVIII peptides that bound to a given HLA-DRB1 protein, e.g. the FVIII-M2238 variant to DR0301 and DR1104 and the E1241 variant to DR0101, but they also incorrectly predicted many binding interactions that were not confirmed experimentally (supplemental Tables 4 and 5 
0
Tetramer-Guided Epitope Mapping:
Twenty-three subjects whose T-cell responses were evaluated using tetramers had clinical records indicating that they had been infused with 'sequence-mismatched' FVIII products, and five additional control subjects whose F8 gene encoded M2238 were also tested ( Table 7) .
None of the experiments using tetramers loaded with FVIII peptides produced unambiguous, tetramer-high staining. In contrast, 23/31 experiments carried out using tetramers loaded with tetanus peptides produced promising tetramer staining of the CD4 high cells, with over half of these showing strong, unambiguous staining of a tetramer-high population ( Figure 3 and supplemental Figure S1 ). Some of the cultures stimulated with F8 SNP-Pool 2238 peptides showed low-level, possibly nonspecific staining by tetramers loaded with these peptides. One of these was from a SE Asian control subject who had been partially tolerized and whose F8 gene encoded FVIII-M2238 ( Figure 3A ). His immune response was queried further, as he had a current inhibitor and so was expected to have FVIII-specific T cells. His cells were incubated for two more days following the initial tetramer-staining experiment and then cultured with tetramers loaded with the individual FVIII peptides. Despite weak tetramer-positivity ( Figure 3B ), the small number of tetramer-positive CD4 T cells were single-cell sorted and expanded in culture in an unsuccessful attempt to generate FVIII-specific T-cell clones and lines ( Figure 3C ). Attempts were also made to isolate FVIII-specific T-cell clones and polyclonal lines recognizing polymorphic sequences at FVIII-2238 from subjects GIS-002-033 and GIS-007-029 (both tolerized to FVIII) and GIS-007-002 (no inhibitor history) (supplemental Table 6 ) by sorting the few tetramer-positive cells and culturing them under expansion conditions. No FVIII-specific clones were obtained, indicating the background-level tetramer staining was nonspecific or that the cells had low avidity for tetramers or were anergic (e.g. in successfully tolerized subjects).
Similar negative results were obtained using cells from six subjects infused with FVIII products mismatched at residue FVIII-1241 (Table 7, supplemental Table 6 and supplemental Figure S1 ).
In contrast, 21/30 positive control experiments carried out in parallel using CD4 T cells from 26 1 1 of the 28 HA subjects produced strong staining by tetramers loaded with tetanus-derived peptides, and borderline tetanus-positive staining was seen for cells from two additional subjects [25] ( Figure 3D , supplemental Figure S1 and supplemental Table 6 ).
In conjunction, these results indicate that deleterious immune responses to FVIII regions encoded by non-hemophilic ns-SNPs occur much less frequently than might have been anticipated based on peptide-MHC binding data and/or T-cell epitope prediction algorithms. This was true even for HA patients whose MHC Class II (HLA-DRB1) were capable of binding FVIII peptides that were mismatched to the sequence encoded by their hemophilic F8 gene (Table 6 ).
Discussion
African American HA patients have been reported to have an increased incidence of FVIII inhibitors vis-à-vis Caucasian patients [9] [10] [11] . An earlier study of 76 Black HA subjects suggested that infusions with 'sequence-mismatched' FVIII may be a risk factor for inhibitor development [14] . Subsequent studies have not shown a statistical link between F8 polymorphisms and inhibitor incidence [27] [28] [29] . The present study focuses primarily on inhibitor incidence in patients with severe HA. Seven subjects who had an intron-22 inversion mutation but baseline clotting activity ≥ 1% normal were also included, as they are not expected to circulate FVIII. We thus avoided possible confounding due to variable inhibitor risks associated with mutations causing mild/moderately severe HA.
No significant correlations were seen between inhibitor history and either F8 haplotypes or the individual ns-SNPs encoding FVIII-D1241E and FVIII-M2238V variants. Only one severe HA subject had the polymorphism encoding FVIII-H484. A logistic regression analysis adjusting for age range, F8 haplotype and potential exposure to 'sequence-mismatched' FVIII was carried out, in which all subjects who had received plasma-derived FVIII and/or any other blood product were assumed to have been exposed to 'sequence-mismatched' FVIII. These subjects showed an increased inhibitor incidence but there was no correlation with F8 haplotypes (Table 5) . No firm conclusions can be drawn from this apparent association, because the sequences of the infused FVIII could be confirmed only for subjects treated with recombinant full-length FVIII products. Furthermore, other product-related, genetic or environmental differences affecting immunogenicity, e.g. between subjects requiring or not requiring blood transfusions, or treated with single versus multiple FVIII products, could not be quantified or ruled out.
African Americans with an intron-22 inversion mutation had a ~3X higher inhibitor risk than
Caucasian subjects with the same mutation, consistent with a recent report of inhibitor incidence in a South African cohort [28] . Multiple-exon deletions have been shown to carry the largest inhibitor risk for patients with severe HA, whereas missense mutations and small insertions/deletions carry lower risks [2] . The race-associated inhibitor risks associated with these types of mutations could not be determined because the subgroups in this study were too small. Previous studies investigating possible associations between HLA and inhibitor incidence have identified weak associations with HLA alleles including HLA-DR15 [30, 31] , however the diversity of HLA repertoires in inhibitor patients is consistent with the multifactorial origin of inhibitor development [32] [33] [34] [35] . A possibly increased inhibitor risk was seen for subjects with HLA-DR15 and the H2 haplotype (Table 4) , but this was not seen for those with peak titers >5 BU/mL (supplemental Table 3 1241 and 2238 (Table 6) . A fourth polymorphic site encoding FVIII-R776G (identified in a SE Asian subject) [13] was also investigated. The two computer algorithms tended to over-predict productive peptide-MHC binding (supplemental Tables 4 and 5) . Such predictions will nevertheless be useful in future studies to determine the MHC-binding registers within peptides shown experimentally to bind specific HLA-DRB1 proteins.
MHC Class II binding is required for peptide presentation on antigen-presenting cells.
Individuals whose MHC effectively bind these peptides could be at higher risk for inhibitor genes encoded FVIII-V2238 never developed a clinically significant inhibitor even though two had HLA-DRB1 (HLA-DR0101 and HLA-DR1101) that bound mismatched FVIII-M2238 peptides with moderate affinity. An additional two subjects expressed HLA-DR0301, which bound with high affinity to a peptide having the mismatched M2238 sequence (Table 6 ).
4
All African American subjects with endogenous F8 sequences encoding FVIII-H484 or FVIII-V2238 (and one subject with FVIII-V2238 who self-identified as Caucasian) had been infused with 'sequence-mismatched' FVIII. Peptides containing R484H or M2238V bound with strong-tomoderate affinity to HLA-DRB1 proteins DR1501, DR0301, DR1104, DR0403 and DR0404
(R484H) and to DR0101, DR0301, DR0403, DR0404, DR1101 and DR1104 (M2238V), respectively. Together the corresponding HLA-DRB1 alleles are found in ~11% and ~20% of the African American population[20, 3 9 ] . Peptides containing D1241E bound with strong-tomoderate affinity to HLA-DRB1 proteins DR0403 and DR0901. Interestingly, two subjects with an HLA-DRB1*09:01 allele, who had been treated with FVIII-E1241, had no inhibitor history and no T-cell response to FVIII-E1241 peptides (Table 7 and supplemental Figure S1 ).
We and others have used tetramer-based protocols to query CD4 T-cell responses in mild HA subjects, unambiguously identifying T-cell epitopes corresponding to wild-type FVIII sequences at hemophilic mutation sites by isolation of FVIII-specific T-cell clones and lines [6] [7] [8] 40 , 41].
The relative incidence of inhibitors in mild HA patients varies with mutation, with several recurrent mutations such as R593C and R2150H having a stronger association with inhibitor development [6, [42] [43] [44] [45] . The present study did not identify T-cell epitopes corresponding to the most common F8 polymorphisms in the African American population, D1241E and M2238V, while control experiments carried out using aliquots of the same blood samples routinely produced distinct tetramer-positive populations from which tetanus-specific T-cell clones and polyclonal lines could be expanded.
The immunogenicity of FVIII sequences encoded by non-HA-causing ns-SNPs has not yet been evaluated using blood samples from HA subjects receiving their initial FVIII infusions, and some patients may develop effector T-cell responses to these sequences. Epitope maturation or drift (Table 6 ), suggesting this polymorphism could confer risk of an immune response to FVIII products mismatched at this site in some patients. However, the low prevalence of this F8 variant indicates that immune responses to epitopes containing FVIII-R484 could not account for an appreciable fraction of inhibitors in African Americans.
The present study evaluated samples and data from 372 African American and Caucasian HA subjects. Both statistical analysis and T-cell stimulation assays strongly indicated that currently available FVIII products have not provoked T-cell responses to potential neo-epitopes encoded by ns-SNPs in an appreciable fraction of African American HA patients. Although T-cell stimulation by such neoepitopes may well occur in some patients, their frequency is unlikely to exceed the inhibitor incidence associated with most F8 missense mutations [2, [45] [46] [47] . In order to better define subsets of patients that might be at risk for immune responses to FVIII sequences encoded by these ns-SNPs, additional studies of patients with potentially higher-risk HLA alleles (that bind these sequences with moderate-to-high affinity), and of patients receiving initial FVIII infusions, are warranted. The present study confirmed that African Americans with severe HA experience a higher inhibitor incidence than Caucasians, and African American subjects with the most common HA-causing mutation, an intron-22 inversion, were found to have a threefold-higher inhibitor risk. Future studies of the complex etiology of inhibitor development will address this significant health disparity. High responder inhibitors >5 BU/ml (African American) 40 (23%) 32 (22%) >5 BU/ml (Caucasian) 32 (16%) 27 (15%) *Probands were defined as the first member of each family group enrolled. † INH = inhibitor. The INH(+) subjects included 13 (entire cohort) and 11 (severe HA probands) with chart notes indicating they had a previous inhibitor, but with no numeric peak titer recorded.
For The study cohort consisted of all severe HA subjects plus seven intron 22 inversion subjects with reported mild or moderate severity HA. These seven subjects were included because, given the fact that intact FVIII protein cannot be translated from mRNA of inversion mutation patients, their clotting activity was presumably due to other coagulation factors besides FVIII. Therefore, it would not be expected to influence anti-FVIII immune responses. All of the pairwise comparisons of individual F8 haplotypes, and all possible subgroupings of these haplotypes, were evaluated for A, C and AA+C racial groups (not shown). None of these comparisons showed a statistically significant association of F8 haplotype with inhibitor risk. *Relative risks of developing an inhibitor were evaluated for the indicated subgroups of African American (AA) and Caucasian (C) HA subjects. † Positive inhibitor status (INH(+)) indicates the clinical record for this subject showed he had at least one measured inhibitor titer of ≥ 0.6 Bethesda units(BU)/ml. ‡ Odds ratios and probabilities were determined using the calculator at http://vassarstats.net/odds2x2.html to determine Fisher's exact 2-way probabilities. P values <0.05 were considered significant. § Haplotypes could not be assigned to 10 of the 372 subjects due to lack of DNA or poorly resolved sequence data.
For personal use only. on April 12, 2017 . by guest www.bloodjournal.org From The study cohorts consisted of all F8-haplotyped severe HA subjects plus seven intron 22 inversion subjects with reported mild or moderate severity HA. *Relative risks of developing an inhibitor were evaluated for the indicated subgroups of African American (AA) and Caucasian (C) HA subjects. † Positive inhibitor status (INH(+)) indicates the clinical record showed at least one measured inhibitor titer of ≥ 0.6 BU/ml. ‡ The multivariate logistic analyses adjusted for age (under or over age 18), F8 haplotype, family relationships and potential exposure to 'sequence-mismatched' FVIII. P values <0.05 were considered significant. § Subjects age 4 and over were considered to be multiply-infused with FVIII. Subjects potentially exposed to 'sequence-mismatched' FVIII included all who had been exposed to blood products, e.g. blood transfusions or FEIBA to control bleeding. The risk factors calculated for this subgroup should be interpreted with caution due to possible confounding from clinical conditions requiring treatment with bloodderived products. Comparisons of individual (e.g. H2 vs. H1) and alternatively grouped (e.g. H1 vs. H3+H4+H5) F8 haplotypes (not shown) showed no statistically significant differences in inhibitor risk.
For personal use only. on April 12, 2017 . by guest www.bloodjournal.org From *AA = African American, C = Caucasian, SEA = SE Asian. † Inhibitor titers in Bethesda Units (BU)/mL were not available for all subjects on the day of sample collection, therefore the most recently determined titers are reported.
‡ HGVS: Human Genome Variation Society nomenclature, in which residue #1 is the first residue of the signal peptide. Int22 = intron 22 inversion. Int1 = intron 1 inversion. ND = Not Determined. § Legacy nomenclature, in which residue #1 is the first residue of the FVIII protein after signal peptide removal. | Alleles with the suffix "g" are the most likely of multiple alternative genotypes encoding identical protein sequences in the HLA-DRB1 antigen recognition site.
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Bolded HLA-DRB1 identifiers indicate that the corresponding HLA-DRB1 tetramers were used to analyze CD4 T-cell responses for these subjects. Cells from mild HA subject 001-043 were analyzed because his F8 gene encoded FVIII-V2238. Cells from mild HA subject 005-015 were analyzed because he had a recently resolved inhibitor. 5/15 subjects with an inhibitor history did not receive ITI. One of these (008-006) had his inhibitor diagnosed at enrollment and one (005-015) had received FVIII only to support surgery.
For personal use only. on April 12, 2017 . by guest www.bloodjournal.org From was found in an Asian subject of an earlier study [13] . Shaded boxes indicate amino acid variants (single-letter code) that are not present in currently available recombinant FVIII products). 
